Chemocentryx, Inc.

Arcus Biosciences, Inc.

Andrew M K Pennell

Penglie Zhang

Wei Yu Chen

Solomon Ungashe

Sreenivas Punna

Trevor T Charvat

Yibin Zeng

Daniel J Dairaghi

Edward J Sullivan

Lianfa Li

William L Thomas

Cheng Hu

Anita Melikian

Aaron Robert Novack

Jeff Jin

Manmohan Reddy Leleti

James Bradley Aggen

Yandong Li

Subhabrata Bapi Sen

Zheng Wei

Jimmie L Moore

Kevin Lloyd Greenman

John Jessen Wright

John J Kim Wright

J J Kim Wright

Derek Hansen

Arindrajit Basak

Jay Patrick Powers

Yuan Xu

Brian E McMaster

Qiang Wang

Antoni Krasinski

Xuefei Tan

Eric F Connor

Valeri Martichonok

Mark M Gleason

Stephen Edmund Gottschling

Mohammed Asadullah Khan

Jim Dimetrios Colomvakos

Jj Kim Wright

Subrabrata Sen

Wei Chen

John Kim J Wright

Subharata Sen

Daniel Joseph Dairaghi

Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

Crystalline forms of a CD73 inhibitor and uses thereof

Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5&#x2032;-nucleotidase, ecto is also provided.

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

Heteroaryl sulfonamides and CCR2/CCR9

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Azaindazole compounds and methods of use

A novel crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy -pyridine-4-carbonyl)-phenyl]-benzenesulfonamide and pharmaceutical compositions containing the same are disclosed. Processes for the preparation thereof and methods for use thereof are also disclosed.

Crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

3-(imidazolyl)-pyrazolo[3,4-b] pyridines

Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Triazolyl phenyl benzenesulfonamides

Triazolyl pyridyl benzenesulfonamides

Provided are methods for the treatment of rheumatoid arthritis using compounds of formula Ia and Ib: or a pharmaceutically acceptable salt, hydrate or N-oxide thereof.

Substituted piperazines

N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides

Growing community of inventors

San Francisco, CA, United States of America

Andrew M K Pennell